Amoxicillin-Clavulanate for Community-Acquired Pneumonia

Introduction to Amoxicillin-Clavulanate

The American College of Physicians and other medical societies recommend amoxicillin-clavulanate as an effective antibiotic for community-acquired pneumonia, particularly when beta-lactamase-producing organisms or penicillin-resistant S. pneumoniae are suspected, with a strength of evidence level of high 1, 2

Adult patients with risk factors such as recent antibiotic use, close contact with individuals receiving antibiotics, failed previous antibiotic therapy, smoking or exposure to secondhand smoke, age >65 years, comorbidities or immunocompromised status, or moderate to severe infection should be treated with amoxicillin-clavulanate 1, 2, 3
Pediatric patients (<5 years) with incomplete H. influenzae type b vaccination, concurrent purulent acute otitis media, daycare attendance, or recent antibiotic treatment should be treated with amoxicillin-clavulanate 2, 3, 4

The standard dose for adults is 500 mg/125 mg three times daily or 875 mg/125 mg twice daily for 7-10 days, with a high-dose option of 2000 mg/125 mg twice daily for resistant pathogens 1, 3
The standard dose for pediatrics is 45 mg/kg/day of amoxicillin component divided into 2-3 doses, with a high-dose option of 80-90 mg/kg/day of amoxicillin with 6.4 mg/kg/day clavulanate in 2 divided doses 2, 3, 4

Adults should be treated for 7-10 days for most cases, with 14 days for bronchiectasis exacerbations 1, 3
Children should be treated for 10 days for bacterial pneumonia, with 5 days sufficing for non-severe cases 2, 3

Multiple RCTs confirm non-inferiority to fluoroquinolones with better antimicrobial stewardship profile, with a strength of evidence level of high 1, 5

Combination therapy with a macrolide should be considered for hospitalized patients with severe CAP or bacteremic pneumonia, as it shows mortality benefit 1, 5
Monotherapy with amoxicillin-clavulanate is appropriate for outpatient mild-moderate CAP 1
High-dose therapy should be used in high-risk situations to avoid treatment failure with resistant organisms 3, 4
Response should be assessed at 48-72 hours, with fever resolution expected within 24-48 hours for pneumococcal pneumonia 2, 6

The Infectious Diseases Society of America recommends using 1000mg/125mg (1.2g) IV/PO every 8 hours for moderate severity pneumonia, as this dosing regimen achieves adequate drug exposure against resistant pathogens 7
For patients with known local prevalence of penicillin-resistant Streptococcus pneumoniae (PRSP), the use of 2000mg/125mg twice daily formulation is recommended, as it achieves 95-98% clinical success rates against PRSP, including strains with amoxicillin-clavulanate MICs up to 4-8 mg/L 7

For methicillin-susceptible Staphylococcus aureus pneumonia, the use of 1.2g IV/PO every 8 hours is recommended 7
For β-lactamase-producing Haemophilus influenzae, the use of 1.2g IV/PO every 12 hours is recommended 7
For penicillin-resistant pneumococcus (MIC >4 mg/L), consideration should be given to switching to ceftriaxone, levofloxacin, or high-dose amoxicillin 3g/day 7

The addition of a macrolide (azithromycin 500mg day 1, then 250mg daily × 4 days) or respiratory fluoroquinolone is recommended for hospitalized patients with severe CAP, bacteremic pneumococcal pneumonia, or suspected atypical pathogens (Mycoplasma, Legionella, Chlamydophila) 7, 8